Why people with Hemophilia A of Mexican descent develop antibodies to factor VIII
Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent
This project uses genetic and immune testing to learn why people with Hemophilia A of Mexican ancestry more often develop antibodies that block therapeutic factor VIII.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project ID | NIH-11180308 on NIH RePORTER |
What this research studies
If you join, researchers will collect health information and blood samples from 200 people with severe Hemophilia A of Mexican ancestry and combine these with about 400 existing participants to create a large dataset. They will run whole-genome sequencing, mRNA sequencing, and CD4 T-cell functional tests to study immune reactions to therapeutic factor VIII. The team will record each person's F8 gene mutation type and whether they have FVIII antigen (CRM) to see how genetics and biology affect antibody risk. Visits will take place at clinics in the United States and Mexico for blood draws and clinical data collection.
Who could benefit from this research
Good fit: Ideal candidates are people with severe Hemophilia A of Mexican ancestry who can provide blood samples and medical history, whether or not they already have FVIII inhibitors.
Not a fit: People without Hemophilia A, people with Hemophilia B, or those not of Mexican ancestry are unlikely to gain direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could help predict who is at high risk for inhibitors and guide safer, more personalized treatment choices.
How similar studies have performed: Previous genetic and immune studies have identified some risk factors for FVIII inhibitors, but combining whole-genome, transcriptome, and CD4 T-cell functional data in this specific population is largely novel.
Where this research is happening
Edinburg, United States
- University of Texas Rio Grande Valley — Edinburg, United States (Active)
Researchers
- Principal investigator: Howard, Tom Eugene — University of Texas Rio Grande Valley
- Study coordinator: Howard, Tom Eugene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.